OvaScience is a global fertility company dedicated to improving treatment options for women around the world. OvaScience is discovering, developing and commercializing new fertility treatments. Each OvaScience treatment is based on the Company’s proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPCSM) cells – immature egg cells found inside the protective ovarian lining. The AUGMENTSM treatment, a fertility option specifically designed to improve egg health, is available in certain IVF clinics in select international regions outside of the United States. OvaScience has commenced a non-commercial preceptorship program with OvaPrimeSM treatment, which could increase a woman’s egg reserve, and is developing the OvaTureSM treatment, a potential next-generation IVF treatment that could help a woman produce healthy, young, fertilizable eggs without hormone injections.

Type
Public
HQ
Waltham, US
Founded
2011
Size (employees)
118 (est)
OvaScience was founded in 2011 and is headquartered in Waltham, US
Report incorrect company information

Key People/Management at OvaScience

Chris Kroeger

Chris Kroeger

CEO
David Sinclair

David Sinclair

Co-Founder & Scientific Advisor

OvaScience Office Locations

OvaScience has an office in Waltham
Waltham, US (HQ)
9 4th Ave
Show all (1)
Report incorrect company information

OvaScience Financials and Metrics

OvaScience Financials

OvaScience's revenue was reported to be $653 k in FY, 2016
USD

Revenue (Q1, 2017)

63 k

Net income (Q1, 2017)

(14.9 m)

EBIT (Q1, 2017)

(14.6 m)

Market capitalization (18-Apr-2018)

30.8 m

Cash (31-Mar-2017)

25.4 m
OvaScience's current market capitalization is $30.8 m.
Annual
USDFY, 2016

Revenue

653 k

General and administrative expense

49.2 m

R&D expense

21.6 m

Operating expense total

70.9 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

15 k30 k75 k146 k189 k197 k63 k

General and administrative expense

5.1 m11 m13.1 m12.9 m14.5 m11.2 m12.6 m7.1 m

R&D expense

4.5 m5.3 m5.7 m4 m4 m6 m6 m5 m5.8 m

Operating expense total

9.6 m5.3 m16.8 m17.1 m16.9 m20.4 m17.2 m17.6 m12.9 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

18.1 m6.4 m43.2 m43.9 m

Inventories

650 k1.6 m3 m2.1 m

Current Assets

45.1 m61.9 m129.9 m116.4 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

16.6 m12.1 m134.7 m70.2 m50.8 m20.5 m95.9 m50.5 m25.4 m

Current Assets

82.6 m73.6 m171.3 m159.2 m145.3 m112.7 m150.1 m133.5 m101.2 m

PP&E

1.9 m3.1 m4.2 m4.2 m6.7 m8.7 m8.1 m8 m4.7 m

Total Assets

85.8 m77.5 m175.8 m164.5 m152.8 m122.1 m158.7 m142.4 m106.3 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(2.6 m)(49.5 m)(73.2 m)(82.3 m)

Depreciation and Amortization

450 k1.3 m2.2 m

Accounts Payable

276 k2.3 m(171 k)(1.2 m)
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(9.9 m)(12.9 m)(17.2 m)(17.5 m)(17.9 m)(21.8 m)(18.6 m)(19.3 m)(14.9 m)

Accounts Payable

1.4 m3 m2.5 m3 m4.2 m4.2 m2.5 m2.8 m2.4 m
USDY, 2017

Revenue/Employee

533.9

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information